Equip ISGlobal

Andrea Alemany is a Marie Sklodowska-Curie Global Fellow (MSCA-PF-GF) leading the RISE-ARBB project (Enhancing the Risk Stratification of Severe Arboviral Diseases using Host-Response Biomarkers in Brazil) at ISGlobal (Spain) and FIOCRUZ-Amazônia (Brazil). She completed her Family Medicine training in 2019, earned a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine in 2023, and obtained her PhD at the University of Barcelona in 2024.

Her predoctoral research from 2020 to 2024 at Fight Infections Foundation focused on the epidemiology and evaluation of diagnostic and therapeutic tools for the management of emerging viral diseases, as well as other neglected tropical infections. She has designed and coordinated large clinical studies and her PhD contributed to shaping global policies on passive immunotherapies for COVID-19. Her research during the 2022 mpox outbreak informed international infection control policies. 

Her research has spanned multiple countries, including Spain, Papua New Guinea, Ghana, Mexico, Peru, Chile, Mozambique, Gabon, Ethiopia, and Brazil. Since January 2024, she has joined Prof. Quique Bassat and Dr. Bàrbara Baro's team at the ISGlobal, focusing on innovative point-of-care prognostic tools based on host-response biomarkers to strengthen risk stratification of severe infections.

Línies de recerca

•  Novel biomarker-based prognostic tools to enhance risk stratification of emerging viral diseases.
• Novel biomarker-based prognostic tools to enhance triage and risk stratification of children with febrile illnesses in Sub-Saharan Africa.
• Early treatment and prevention of COVID-19 using passive immunotherapies, including convalescent plasma and hyperimmune immunoglobulins.
• Evaluation of rapid point-of-care diagnostic tools for COVID-19.
• Characterization of clinical presentation, epidemiology, viral clearance, immune responses, and vaccine efficacy during mpox global outbreak.

Publicacions principals

• Alemany A* (CA), Millat-Martinez P*, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022 Mar;10(3):278-288. 
• Mitjà O*, Alemany A*, Marks M*, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, Corral Herrera EA, Crabtree-Ramirez B, Blanco JL, Girometti N, Mazzotta V, Hazra A, Silva M, Montenegro-Idrogo JJ, Gebo K, Ghosn J, Peña Vázquez MF, Matos Prado E, Unigwe U, Villar-García J, Wald-Dickler N, Zucker J, Paredes R, Calmy A, Waters L, Galvan-Casas C, Walmsley S, Orkin CM; SHARE-NET writing group. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023 Mar 18;401(10380):939-949. 
• Alemany A (CA), Millat-Martinez P, Corbacho-Monné M, Suñer C, Galvan-Casas C, Carrera C, Ouchi D, Prat N, Ara J, Nadal N, Riel R, Funollet B, Ojeda-Ciurana C, Balague LE, Salvador-González B, Arcarons AF, Vidal-Alaball J, Del Cura-González MI, Barrientos RR, Ramos-Blanes R, Bou AA, Mondou E, Torres M, Campins N, Sanz A, Tang Y, Rodriguez-Arias MÀ, Bassat Q, Clotet B; GC2010 STUDY GROUP; Mitjà O. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine. 2023 Mar 10;57:101898. 
• Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, Arando M, Arroyo-Andrés J, Calderón-Lozano L, Casañ C, Cabrera JM, Coll P, Descalzo V, Folgueira MD, García-Pérez JN, Gil-Cruz E, González-Rodríguez B, Gutiérrez-Collar C, Hernández-Rodríguez Á, López-Roa P, de Los Ángeles Meléndez M, Montero-Menárguez J, Muñoz-Gallego I, Palencia-Pérez SI, Paredes R, Pérez-Rivilla A, Piñana M, Prat N, Ramirez A, Rivero Á, Rubio-Muñiz CA, Vall M, Acosta-Velásquez KS, Wang A, Galván-Casas C, Marks M, Ortiz-Romero PL, Mitjà O. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-669. doi: 10.1016/S0140-6736(22)01436-2. Epub 2022 Aug 8. Erratum in: Lancet. 2022 Dec 10;400(10368):2048. 
• Alemany A, Balanza N, Millat-Martinez P, Ouchi D, Corbacho-Monné M, Morales-Indiano C, Fernández Rivas G, Blanco I, Mitjà O, Aguilar R, Dobaño C, Bassat Q, Moncunill G, Baro B; COnV-ert BMK STUDY GROUP. Prognostic performance of early immune and endothelial activation markers in mild-to-moderate COVID-19 outpatients: a nested case-control study. Front Immunol. 2024 Nov 27;15:1501872. doi: 10.3389/fimmu.2024.1501872. PMID: 39664394; PMCID: PMC11631913.
• Millat-Martinez P*, Gharbharan A*, Alemany A*, Rokx C, Geurtsvankessel C, Papageorgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monné M, Ouchi D, Piccolo Ferreira F, Malchair P, Videla S, García García V, Ruiz-Comellas A, Ramírez-Morros A, Rodriguez Codina J, Amado Simon R, Grifols JR, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitjà O, Rijnders BJA; CoV-Early study group; COnV-ert study group. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun. 2022 May 11;13(1):2583.